Commentary on Glanz et al.: Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?

Suzanne Nielsen; Sarah Larney

doi:10.1111/add.16032

Commentary on Glanz et al. Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?

Suzanne Nielsen
, Sarah Larney

Research output: Contribution to journal › Comment / Debate › Other

Original language	English
Pages (from-to)	108-109
Number of pages	2
Journal	Addiction
Volume	118
Issue number	1
DOIs	https://doi.org/10.1111/add.16032
Publication status	Published - Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Buprenorphine
mortality
overdose
retention
stigma
treatment duration

Access to Document

10.1111/add.16032Licence: CC BY-NC-ND

Cite this

@article{2b79deb9cfba4c40bc91eb969782ef3e,

title = "Commentary on Glanz et al.: Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?",

keywords = "Buprenorphine, mortality, overdose, retention, stigma, treatment duration",

author = "Suzanne Nielsen and Sarah Larney",

note = "Funding Information: S.N. is a named investigator on an implementation trial of depot buprenorphine funded by Indivior. S.L. has received untied educational grant funding from Indivior. ",

year = "2023",

month = jan,

doi = "10.1111/add.16032",

language = "English",

volume = "118",

pages = "108--109",

journal = "Addiction",

issn = "0965-2140",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Commentary on Glanz et al.

T2 - Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?

AU - Nielsen, Suzanne

AU - Larney, Sarah

N1 - Funding Information: S.N. is a named investigator on an implementation trial of depot buprenorphine funded by Indivior. S.L. has received untied educational grant funding from Indivior.

PY - 2023/1

Y1 - 2023/1

KW - Buprenorphine

KW - mortality

KW - overdose

KW - retention

KW - stigma

KW - treatment duration

UR - https://www.scopus.com/pages/publications/85137247775

U2 - 10.1111/add.16032

DO - 10.1111/add.16032

M3 - Comment / Debate

AN - SCOPUS:85137247775

SN - 0965-2140

VL - 118

SP - 108

EP - 109

JO - Addiction

JF - Addiction

IS - 1

ER -

Commentary on Glanz et al. Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?

UN SDGs

Keywords

Access to Document

Other files and links

Cite this